Symbiotec Pharmalab opens Rs 1,757 crore IPO, per SEBI RHP filing

The Development

Symbiotec Pharmalab Limited opened its initial public offering for subscription on Monday, 24 August 2026, per the red herring prospectus (RHP) filed with the Securities and Exchange Board of India, whose abridged prospectus is available on SEBI's website. The Indore-based active pharmaceutical ingredient (API) maker's offer is a book-built issue aggregating up to Rs 17,570.00 million, roughly Rs 1,757 crore, comprising a fresh issue of up to Rs 1,500.00 million, about Rs 150 crore, and an offer for sale of up to Rs 16,070.00 million, about Rs 1,607 crore, by three selling shareholders.

Per the bid programme in the RHP, the anchor bidding date was Friday, 21 August 2026, and the bidding window closes on Thursday, 27 August 2026. BSE is the designated stock exchange, with both BSE and NSE having granted in-principle approvals by letters dated 4 February 2026. This development was surfaced through coverage on the IPO desk of The Economic Times; the figures here are drawn from the offer document lodged with SEBI.

The Company

The company describes itself in the RHP as "a research and development-driven, science-based pharmaceutical and biotechnology company" with capabilities across three platforms: organic chemistry, biotechnology and complex injectables. It operates as a contract development and manufacturing organisation (CDMO) for specialty pharmaceutical and nutraceutical companies globally, and also manufactures its own products. The company discloses that it primarily operates in the API industry and claims "global leadership in corticosteroid and steroidal-hormone APIs". As of 31 March 2026, it reported over 50 domestic and over 150 export customers. Its registered office is near Indore in Madhya Pradesh, and its promoters are Anil Satwani, Kashish Satwani, Sushil Satwani and Satwani Holdings LLP.

On the numbers, the company discloses restated consolidated revenue from operations of Rs 8,691.49 million in Fiscal 2026, up from Rs 7,515.54 million in Fiscal 2025 and Rs 7,162.47 million in Fiscal 2024. Profit after tax was Rs 1,099.03 million in Fiscal 2026, against Rs 967.85 million in Fiscal 2025 and Rs 1,000.55 million in Fiscal 2024, per the RHP. EBITDA for Fiscal 2026 was Rs 2,319.73 million and net worth was Rs 11,586.41 million, with a return on net worth of 9.48 per cent. Basic earnings per equity share were Rs 19.10 in Fiscal 2026.

The Offer Structure

Per the RHP, the offer combines a fresh issue by the company and an offer for sale by existing holders. The fresh component is up to Rs 1,500.00 million and the offer for sale up to Rs 16,070.00 million, taking the total to Rs 17,570.00 million at a face value of Rs 2 per share. The selling shareholders named in the document are Satwani Holdings LLP, a promoter selling shareholder, offering up to Rs 1,440.00 million; Rosewood Investments, up to Rs 9,880.00 million; and India Business Excellence Fund - III, up to Rs 4,750.00 million. The price band and lot size were fixed in the price-band advertisement issued ahead of the opening and are set out on the exchanges; the RHP carries these as to-be-finalised entries.

On the use of proceeds, the company states it proposes to utilise up to Rs 1,125.00 million from the net fresh-issue proceeds towards "prepayment and/or repayment, in full or in part," of certain borrowings, with the balance for general corporate purposes. Standalone fund-based borrowings stood at Rs 3,497.81 million as at 31 March 2026, per the RHP. The book-running lead managers are JM Financial, Avendus Capital, Motilal Oswal Investment Advisors (involved only in marketing the offer) and Nomura Financial Advisory and Securities (India); the registrar is MUFG Intime India. Readers working through the arithmetic of an allotment may find Oquilia's lumpsum calculator and CAGR calculator useful, and prior coverage sits on the Oquilia news desk.

Risk Factors

The offer document sets out its top internal risk factors, which are the company's own required disclosures rather than any assessment by this desk. The RHP lists customer and product concentration prominently: it discloses that APIs constituted 96.07 per cent, 99.10 per cent and 100.00 per cent of revenue from operations in Fiscals 2026, 2025 and 2024, and that its top five APIs made up 67.27 per cent of Fiscal 2026 revenue. Among the risks the company discloses, its top ten customers accounted for 57.59 per cent of revenue from sale of product in Fiscal 2026.

The document also flags export dependence, noting that revenue from customers outside India represented 67.04 per cent of operations in Fiscal 2026, with United States revenue at 13.12 per cent, and referencing the risk that "the imposition of tariffs or other anti-outsourcing legislation" in the United States could hurt results. The RHP further notes that the manufacturing facilities are subject to periodic regulatory inspections, that any "manufacturing or quality control failures" could invite regulatory action, and that operations and dedicated R&D centres are concentrated in Madhya Pradesh. It adds that the company operates in a highly competitive market and has only recently commenced its CDMO role.

What Happens Next

The mechanics from here follow the standard book-building process described in the RHP. The anchor allocation was completed on 21 August 2026, one working day before the opening, and the three-day public bidding window runs to 27 August 2026, with the UPI mandate cut-off at 5:00 p.m. on the closing day. After the close, the registrar finalises the basis of allotment; investors who are not allotted shares have their blocked funds released, while allottees receive credits to their demat accounts, per the process the offer document sets out.

Listing then follows, with BSE as the designated stock exchange and NSE also carrying the shares. The exact allotment and listing dates are announced through exchange notices once the subscription window closes. Category-wise subscription figures, when reported, come from live NSE and BSE bid data as of a stated time, and the debut price will be an exchange-recorded fact measured against the issue price. This report describes that sequence as process, not as any prediction of demand or price.

FAQ

Should I apply for this IPO?

Oquilia does not make recommendations. This report is informational and is not investment advice or a recommendation to subscribe. The RHP, including the complete risk-factors section, is available on SEBI's website and the exchanges. Read it directly before making any decision.

What is the size and structure of the issue?

Per the RHP, the total offer aggregates up to Rs 17,570.00 million, roughly Rs 1,757 crore. It comprises a fresh issue of up to Rs 1,500.00 million and an offer for sale of up to Rs 16,070.00 million by three named selling shareholders. The face value is Rs 2 per equity share.

When does the issue open and close?

Per the bid programme in the RHP, the anchor bidding date was 21 August 2026, the offer opened on 24 August 2026 and closes on 27 August 2026. The UPI mandate end time is 5:00 p.m. on the closing date, as the offer document states.

What are the objects of the fresh issue?

The company discloses that it proposes to use up to Rs 1,125.00 million of the net fresh-issue proceeds towards prepayment or repayment of certain borrowings, and the balance for general corporate purposes. The offer-for-sale proceeds go to the selling shareholders, not to the company, per the RHP.

Where can I read the RHP?

The red herring prospectus and its abridged version are filed with SEBI and available under the Filings, Public Issues section on sebi.gov.in, and on the BSE and NSE websites. The offer document is the authoritative source for all figures, objects and risk factors.

This report is based on the abridged red herring prospectus filed with SEBI and SEBI's public-issues filings record. It was surfaced via coverage in The Economic Times.